undamentalytics Newsletter
Sign in

Alaunos Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Alaunos Therapeutics, Inc. had total assets of $3.0m, total liabilities of $813,000 and shareholders' equity of $2.2m. It held $1.4m in cash against $0 of debt: net cash of $1.4m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122016Dec 20162017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents1057381716211576396110
Receivables000025100000
Total current assets10680105918413179548321
Total assets108831061069514695658332
Accounts payable220411111111
Deferred revenue (current)1166————————
Total current liabilities1319162191816242111
Short-term debt—————08170———
Long-term debt—————016000——
Total debt00000024170000
Total liabilities3735585892237262111
Shareholders' equity7248−77−978612458396221
Non-controlling interests and other (assets − liabilities − equity)——125144————————
Net debt (negative = net cash)−105−73−81−71−62−115−52−22−6−1−1−0
Shares outstanding————————2m2m2m2m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CELZ vs TCRTLYEL vs TCRTAIM vs TCRT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alaunos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alaunos Therapeutics, Inc.